Boehringer Ingelheim Pharmaceuticals expands drug discovery alliance with Graffinity

15-Dec-2006

High-performance ion exchange resins for biochromatography

Automated cell counting for fast and reliable cell characterization

Image integrity checker software - authenticate your images for publication

Graffinity Pharmaceuticals GmbH announced that its partner Boehringer Ingelheim Pharmaceuticals, Inc. has chosen to exercise options in its original agreement with Graffinity that will significantly increase the number of targets screened by Graffinity as part of this global alliance. Under the terms of the agreement, Graffinity will receive additional technology access fees for the generation of multiple novel small molecule hit series against a variety of drug targets from different therapeutic areas.

Graffinity will apply its proprietary fragment based drug discovery technology and drug fragment chemical microarrays to identify small molecule hit structures focusing on compounds with novel modes of action. Financial details of the transaction were not disclosed.

https://www.bionity.com/en/news/60168/boehringer-ingelheim-pharmaceuticals-expands-drug-discovery-alliance-with-graffinity.html